![](/img/cover-not-exists.png)
1501PImpact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: A REAL-oncology analysis from the I-O Optimise initiative
Snee, M, Cheeseman, S, Thompson, M, Bowman, R, Lacoin, L, Sopwith, W, Chaib, C, Daumont, M, Penrod, J R, O’Donnell, J C, Hall, GVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz260.023
Date:
October, 2019
File:
PDF, 77 KB
2019